°¢¸·ÀÌ½Ä °ÅºÎ¹ÝÀÀ °íÀ§Ç豺¿¡¼ ÀüÃþ°¢¸·À̽ļú ÈÄ Àú¿ë·® »çÀÌŬ·Î½ºÆ÷¸° Åõ¾à¿¡ µû¸¥ ÀÌ½Ä½ÇÆÐÀ²
The Efficacy of Low-Dose Systemic Cyclosporine for Graft Failure after Penetrating Keratoplasty in High-Risk Group
´ëÇѾȰúÇÐȸÁö 2014³â 55±Ç 1È£ p.13 ~ p.19
Á¶¿µÁÖ(Cho Young-joo) - ¿¬¼¼´ëÇб³ Àǰú´ëÇÐ ¾È°úÇб³½Ç ½Ã±â´É°³¹ß¿¬±¸¼Ò
±èÀÀ±Ç(Kim Eung-Kweon) - ¿¬¼¼´ëÇб³ Àǰú´ëÇÐ ¾È°úÇб³½Ç ½Ã±â´É°³¹ß¿¬±¸¼Ò
ÀÌÇü±Ù(Lee Hyung-Keun) - ¿¬¼¼´ëÇб³ Àǰú´ëÇÐ ¾È°úÇб³½Ç ½Ã±â´É°³¹ß¿¬±¸¼Ò
Abstract
¸ñÀû: °¢¸·ÀÌ½Ä °ÅºÎ¹ÝÀÀÀÇ °íÀ§Ç豺 ȯÀÚ¿¡¼ ÀüÃþ°¢¸·À̽ļú ½ÃÇà ÈÄ Àú¿ë·® cyclosporine (CsA) º¹¿ëÀÌ ÀÌ½Ä½ÇÆÐºñÀ²¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÏ¿© ¾Ë¾Æº¸°íÀÚ ÇÏ¿´´Ù.
´ë»ó°ú ¹æ¹ý: °¢¸·ÀÌ½Ä °ÅºÎ¹ÝÀÀ °íÀ§Ç豺¿¡¼ ÀüÃþ°¢¸·À̽ļúÀ» ½ÃÇà¹ÞÀº 25¸í 36¾ÈÀ» ´ë»óÀ¸·Î Àú¿ë·® CsA º¹¿ë¿©ºÎ¿¡ µû¶ó CsA º¹¿ë±º(n=19)°ú ´ëÁ¶±º(n=17)À¸·Î ºÐ·ùÇÏ¿©, ¼ö¼ú ÈÄ 2³â°£ÀÇ ÀÌ½Ä½ÇÆÐÀ²À» ºñ±³Çϰí CsA Åõ¾à±º¿¡¼ ºÎÀÛ¿ë ¹ß»ý ºñÀ²À» Á¶»çÇÏ¿´ ´Ù. Ãß°¡ ºÐ¼®À¸·Î 2ȸ ÀÌ»ó °¢¸·À̽ÄÀ» ¹ÞÀº ȯÀÚ¸¦ CsA º¹¿ë±º(n=9)°ú ´ëÁ¶±º(n=9)À¸·Î ³ª´©¾î Àú¿ë·® CsA º¹¿ë¿©ºÎ¿¡ µû¸¥ ¼ú ÈÄ 2³â°£ÀÇ ÀÌ½Ä½ÇÆÐÀ²À» ºñ±³ÇÏ¿´´Ù.
°á°ú: °¢¸·À̽ļö¼ú 2³â ÈÄ ÀÌ½Ä½ÇÆÐÀ²Àº Àú¿ë·® CsA º¹¿ë±º¿¡¼ 31.6%, ´ëÁ¶±º¿¡¼ 68.4%·Î, Åë°èÀûÀ¸·Î À¯ÀÇÇÑ Â÷À̰¡ ¾ø¾úÀ¸³ª (p=0.311), ±× Áß 2ȸ ÀÌ»óÀÇ ¹Ýº¹°¢¸·À̽ļúÀ» ¹ÞÀº ±º¿¡¼´Â ¼ö¼ú ÈÄ 2³â°£ ÀÌ½Ä½ÇÆÐÀ²ÀÌ Àú¿ë·® CsA º¹¿ë±º¿¡¼´Â 22.2%·Î 77.8% ÀÎ ´ëÁ¶±º¿¡ ºñÇØ À¯ÀÇÇÏ°Ô ³·¾Ò´Ù(p=0.018). ¶ÇÇÑ 2³â°£ÀÇ °æ°ú°üÂû Áß 1¿¹(5.26%)¿¡¼¸¸ À§ÀåÀå¾Ö·Î Åõ¾àÀ» Áß´ÜÇÏ¿´´Ù.
°á·Ð: °¢¸·ÀÌ½Ä °ÅºÎ¹ÝÀÀ °íÀ§Ç豺¿¡¼ ÀüÃþ°¢¸·À̽ļú ÈÄ Àú¿ë·® CsA º¹¿ëÀº 2³â°£ÀÇ ÀÌ½Ä½ÇÆÐÀ²¿¡ ¿µÇâÀ» ÁÖÁö´Â ¾Ê¾ÒÀ¸³ª, ºÎÀÛ¿ë Àº 5.26%·Î ±âÁ¸ ¿¬±¸µé¿¡ ºñÇØ Àû¾úÀ¸¸ç, 2ȸ ÀÌ»óÀÇ ¹Ýº¹°¢¸·À̽ļú ±º¿¡¼´Â ÀÌ½Ä½ÇÆÐÀ²À» ÁÙÀÌ´Â °ÍÀ¸·Î ³ªÅ¸³µ´Ù. 2ȸ ÀÌ»óÀÇ ¹Ýº¹°¢¸·À̽ļú ±º¿¡¼´Â Àú¿ë·® CsAº¹¿ëÀ» °í·ÁÇØ º¼ ¼ö ÀÖÀ¸¸ç, ÀÌ¿¡ ´ëÇÑ Ãß°¡Àû ¿¬±¸°¡ ÇÊ¿äÇÒ °ÍÀ¸·Î »ý°¢ÇÑ´Ù.
Purpose: To investigate the effect of low-dose systemic cyclosporine A (CsA) in preventing graft failure after high-risk penetrating keratoplasty (PKP).
Methods: In this retrospective study, 36 eyes of 25 patients who underwent PKP were evaluated. At 24 months postoperatively, the failure rate in the CsA group (n = 19) was compared to the control group (n = 17). For subgroup analysis, the failure rate in the CsA group (n = 9) and control group (n = 9) was compared in patients who underwent a repeat PKP. The patients¡¯ side-effect profile was also collected.
Results: The median follow-up in the CsA group was 32.8 months and 28.9 months in the control group. Graft failure occurred in 31.6% CsA patients and in 68.4% control patients (p = 0.311). In patients with repeat PKP, the failure rate in the CsA group was significantly lower than the control group (22.2% vs. 77.8%, p = 0.018). In one case (5.26%), CsA was discontinued due to gastroinstestinal discomfort.
Conclusions: Low-dose CsA was not beneficial compared to conventional therapy in high-risk PKP patients. However, in the repeat PKP subgroup, the incidence of graft failure was lower with low-dose CsA than with conventional therapy. Although further study is necessary, adding low-dose CsA might be beneficial for repeat PKP patients.
Ű¿öµå
Corneal graft failure, Cyclosporin A, Penetrating keratoplasty
KMID :
0360220140550010013
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)